Evidence map›Paper›PMID 42430569›Full record

ArticleHematological oncology2026

Intensified Rituximab, Methotrexate, Procarbazine, and Cytarabine (R-MPVA) Regimen With Sequential Addition of Etoposide to R-MPV and Ifosfamide to R-AraC for Newly Diagnosed Primary CNS Lymphoma Patients Aged Between 60 and 70 Years: An LOC Network Study.

Gabriel Antherieu, Edith Julia, Léopoldine Lapierre, Marie Donzel, Caroline Houillier, Carole Soussain, Emmanuelle Nicolas-Virelizier, Philippe Rey, François Ducray, David Meyronet and 5 more

Abstract readMulticenter Study
PubMed Full text at PMC Publisher
In one paragraph

Article in Hematological oncology, 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Gabriel AntherieuDepartment of Hematology, Hopital Lyon Sud, Hospices Civils de Lyon, Claude Bernard Lyon 1 University, Pierre Benite, France.ORCID https://orcid.org/0000-0002-6043-2580
Edith JuliaDepartment of Hematology, Hopital Lyon Sud, Hospices Civils de Lyon, Claude Bernard Lyon 1 University, Pierre Benite, France.
Léopoldine LapierreDepartment of Hematology, IUC CHU Toulouse, Toulouse, France.
Marie DonzelDepartment of Pathology, Hospices Civils de Lyon, Claude Bernard Lyon 1 University, Lyon, France.ORCID https://orcid.org/0000-0002-5797-5744
Caroline HouillierNeuro-oncology Department, Hôpital Pitié-Salpêtrière, IHU, ICM, Inserm, CNRS, Sorbonne Université, Paris, France.
Carole SoussainDepartment of Hematology, Institut Curie, Saint-cloud, France.
Emmanuelle Nicolas-VirelizierDepartment of Hematology, Centre Leon Berard, Claude Bernard Lyon 1 University, Lyon, France.
Philippe ReyDepartment of Hematology, Centre Leon Berard, Claude Bernard Lyon 1 University, Lyon, France.ORCID https://orcid.org/0009-0007-2833-1011
François DucrayDepartment of Neurology, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Claude Bernard Lyon 1 University, Bron, France.
David MeyronetDepartment of Pathology, Hospices Civils de Lyon, Claude Bernard Lyon 1 University, Lyon, France.
Thiébaud PicartDepartment of Neurosurgery, Hôpital Neurologique Pierre Wertheimer, Hospices Civils de Lyon, Claude Bernard Lyon 1 University, Bron, France.ORCID https://orcid.org/0000-0001-6494-6725
Loïc YsebaertDepartment of Hematology, IUC CHU Toulouse, Toulouse, France.
Khê Hoang XuanNeuro-oncology Department, Hôpital Pitié-Salpêtrière, IHU, ICM, Inserm, CNRS, Sorbonne Université, Paris, France.
Lucie ObéricDepartment of Hematology, IUC CHU Toulouse, Toulouse, France.ORCID https://orcid.org/0000-0002-0039-1983
Hervé GhesquièresDepartment of Hematology, Hopital Lyon Sud, Hospices Civils de Lyon, Claude Bernard Lyon 1 University, Pierre Benite, France.ORCID https://orcid.org/0000-0002-3131-3718

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The treatment efficacy, acute toxicity, and neurocognitive sequelae of older patients with primary central nervous system lymphoma (PCNSL) remain therapeutic challenges. The standard first-line therapy consisted of high-dose methotrexate and cytarabine (AraC) and led to a complete response (CR) in half of the patients. To improve the response rate, we proposed intensifying the standard rituximab, methotrexate, procarbazine, vincristine, and cytarabine (R-MPVA) regimen by sequentially adding etoposide (100 mg/m

Indexed as

Antineoplastic Combined Chemotherapy ProtocolsCentral Nervous System NeoplasmsLymphomaAgedCytarabineEtoposideFemaleHumansIfosfamideMaleMethotrexateMiddle AgedProcarbazineRetrospective StudiesRituximabCytarabineEtoposideIfosfamideMethotrexateProcarbazineRituximabetoposideifosfamideolder patientsprimary CNS lymphomaR‐MPVA

Identifiers

PMID42430569
PMCPMC13354274

What Socratic holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.